Tibsovo Approval Makes Agios’ Second AML Approval In A Year; Priced At $26k For 30 Days

Tibsovo is the second targeted therapy approved for a mutation-specific subset of relapsed/refractory AML patients. Agios discovered and jointly markets the first, Idhifa, with Celgene.

Cancer cells on scientific background.3d illustration

Agios Pharmaceuticals Inc. obtained its second approval for a targeted acute myelogenous leukemia drug in less than a year and will soon launch Tibsovo (ivosidenib) for relapsed or refractory AML patients who test positive for an IDH1 mutation. The firm said on July 20 that it set a 30-day wholesale acquisition cost of $26,115 for the drug at a daily dose of 500 mg.

Cambridge, Mass.-based Agios and partner Celgene Corp. won US FDA approval of Idhifa (enasidenib) for the treatment of relapsed or refractory AML patients with an IDH2 mutation in August of last year; that drug launched at $24,872 per month. (Also see "Celgene, Agios Ready For Enasidenib Launch After Early Approval" - Scrip, 1 August, 2017

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from New Products

Pipeline Watch: Eight Approvals And Nineteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

In Brief: US FDA Delay Sends Biohaven Shares Down

 

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Strong Showing For Bayer’s Pharma Business In Uncertain Times

 
• By 

As CEO Anderson backs high prices for innovative drugs in Europe

Biopharma Deals ROI Has Fallen And Market Instability Could Make It Worse

 

Rising biotech valuations mean return on investment on some deals is non-existent for big pharma, though certain strategies will improve chances of success, a new analysis has found.

More from Scrip

Asia Deal Watch: Lilly Partners With Rznomics On Hearing Loss

 

Plus deals involving Minghui/Qilu, LENZ/Lotus, Amicus/Dimerix, Sanofi/Dr. Reddy’s, Henlius/Lotus, Apnimed/Desitin, Formosa/Saval, DAAN/GC Cell, VelaVigo/Ollin and Sol-Gel/Mayne.

Boehringer’s Next Generation IPF Drug Underwhelms

 

The company hoped its follow-up to blockbuster Ofev could clearly improve efficacy and safety benefits, but the full Phase III results from nerandomilast’s FIBRONEER-IPF fall short of a slam dunk.

Affimed’s ASCO ‘Hail Mary’ As Survival Chances Slim

 
• By 

The German biotech has been forced into insolvency and NASDAQ suspension.